Survey: Perception of Gleason 6 (Grade Group 1) Prostate Cancer
There are many management options for men diagnosed with Gleason 6 (Grade Group 1) prostate cancer. Treatment with radiation or surgery remains relatively common. There are significant concerns regarding proper patient counseling, a significant potential for overtreatment, and a possible lack of shared decision-making between physicians and their patients.
Ragheed Saoud, SUO Fellow at the University of Chicago; Alejandro Berlin, Radiation Oncologist at the University of Toronto and Scott Eggener, Urologic Oncologist at the University of Chicago, have developed a survey, evaluating the perception of ISUP Grade Group 1 prostate cancer among treating physicians across multiple specialties (urology, radiation oncology, pathology, etc.). Additionally, the survey will evaluate physician practices across the world to understand their thoughts on how indolent or lethal Gleason 6 prostate cancer is. Additionally, the survey will explore the extent to which very low and low-risk prostate cancer is managed.
The goal is to reach as many people as possible. Once published, results from this study will be a valuable contribution to the literature. The hypothesis being that ISUP GG1 disease remains overtreated due to common misconceptions regarding its true natural history. This hypothesis dovetails with initiatives suggesting GG1 cancer should be considered for renaming and perhaps even eliminate the term ‘cancer’ to better frame the discussion and shared decision-making with patients.
Participation in the survey is completely voluntary and should take approximately 5 minutes to complete.